文献速递胸部肿瘤

晚期NSCLC免疫检查点抑制剂治疗≥4年长期获益者的疾病动力学与实践模式

Disease Kinetics and Practice Patterns in More Than or Equal to 4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2026-07-28

这项多中心回顾性研究纳入2015年1月至2020年4月接受含ICI治疗的晚期NSCLC患者,定义长期获益者(LTB)为OS≥4年且至下一线细胞毒化疗时间≥4年。3144例中537例(17%)生存≥4年,295例(9.4%)为LTB;4年无进展LTB中66%停用ICI,肺癌特异性OS在6年和8年分别为97.8%和88.0%,晚期进展少见且多呈惰性,非肺癌死亡占主导。

要点

  • 晚期NSCLC含ICI治疗者中9.4%达LTB(OS及至下一线化疗均≥4年)。
  • 4年无进展LTB中66%停用ICI,8年肺癌特异性OS达88.0%。
  • ≥4年死亡者中68%为非肺癌原因,需重视全面生存者照护。

核心结论

  • 4年无进展的LTB可实现持久控制,8年随访时肺癌特异性OS接近90%。
  • 晚期进展不常见、范围有限且常呈惰性,部分患者接受局部治疗。
  • 非肺癌相关死亡占主导,凸显全面生存者照护的重要性。

研究设计与样本

  • 多中心回顾性研究,纳入2015年1月至2020年4月接受含ICI治疗的晚期NSCLC患者。
  • LTB定义为OS≥4年且至下一线细胞毒化疗时间≥4年,共295例(9.4%),中位随访68.6个月。
  • 进行4年landmark分析,定义晚期进展为首个影像学进展距ICI启动≥4年,并用竞争风险分析评估死因别死亡。

主要发现

  • 3144例中537例(17%)生存≥4年,295例(9.4%)为LTB,数据截止时仅8.1%失访。
  • 63%的患者ICI为一线治疗;235例4年无进展LTB中66%停用ICI。
  • LTB的肺癌特异性OS在6年和8年分别为97.8%和88.0%。
  • 26例(11.1%)发生晚期进展,所有病灶≤5个,84.6%为生长速度≤10 mm/mo的惰性进展,进展后42%选择局部治疗。
  • ICI后≥4年死亡22例,仅7例(32%)为肺癌相关,15例(68%)为其他原因包括第二原发肿瘤;竞争风险分析显示其他原因死亡持续超过肺癌相关死亡。

临床怎么用

  • 对4年无进展的LTB可考虑停用ICI,因66%已实际停药且肺癌特异性OS仍高。
  • 晚期进展多局限且惰性,局部治疗是可选策略(42%进展后接受局部治疗)。
  • 生存者随访应关注非肺癌死亡原因,包括第二原发肿瘤等。

局限性

  • 回顾性多中心设计可能存在选择偏倚和未测量混杂。
  • LTB定义依赖至下一线化疗时间,可能受治疗实践差异影响。
  • 数据截止时8.1%失访,可能影响长期结局估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have enabled durable responses in a subset of patients with advanced NSCLC; however, the clinical trajectories and patterns of late disease progression among long-term survivors remain poorly characterized. METHODS: This multicenter retrospective study enrolled patients with advanced NSCLC who received ICI-containing therapy between January 2015 and April 2020. Long-term beneficiaries (LTBs) were defined as patients who achieved both an overall survival (OS) of more than or equal to 4 years and a time to next cytotoxic chemotherapy of more than or equal to 4 years. We performed 4-year landmark analyses, characterized late progression (first radiographic progression ≥4 y from ICI initiation), and evaluated cause-specific mortality using competing risk analysis. RESULTS: Of 3144 patients, 537 (17%) survived more than or equal to 4 years, and 295 (9.4%) were LTBs (median follow-up: 68.6 mo); only 8.1% were lost to follow-up at the data cutoff. ICI was initiated as first-line therapy in 63% of the patients. Among the 235 LTBs without progression at 4 years, 66% discontinued ICI. The lung cancer-specific OS rates were 97.8% and 88.0% at 6 and 8 years, respectively. Late progression occurred in 26 patients (11.1%); all had less than or equal to five lesions, and 84.6% demonstrated indolent progression with growth speeds less than or equal to 10 mm/mo. Local therapy was selected in 42% of the patients after progression. Of 22 deaths more than or equal to 4 years post-ICI, only seven (32%) were lung cancer related, whereas 15 (68%) were from other causes, including secondary malignancies. Competing risk analysis revealed that other-cause mortality consistently exceeded lung cancer-related mortality. CONCLUSIONS: LTBs without progression at 4 years achieved durable control, with lung cancer-specific OS approaching 90% at 8 years of follow-up. Late progression is uncommon, limited in extent, and often treated locally. The predominance of non-lung cancer-related mortality underscores the importance of comprehensive survivorship care.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Torasawa M, Masui Y, Miura K, et al. Disease Kinetics and Practice Patterns in More Than or Equal to 4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced NSCLC. J Thorac Oncol. 2026. PMID: 42520967. doi:10.1016/j.jtho.2026.104113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。